Statistical Evaluation of Structure-Activity Relationships (SAR) in Antimalarial Drug Development: A Medicinal Chemistry Perspective

Malaria remains a major global health concern, particularly in Sub-Saharan Africa, where it contributes significantly to morbidity and mortality. The rise of drug-resistant Plasmodium strains poses a serious challenge to current treatment options, underscoring the need for innovative drug development strategies. Medicinal chemistry, particularly the study of structure-activity relationships (SAR), plays a central role in this effort by linking chemical structure with biological activity. This review focuses on the statistical evaluation of SARs in antimalarial drug development. It explores how chemical modifications of lead compounds influence pharmacological efficacy and how statistical models such as Quantitative Structure-Activity Relationships (QSAR) support the prediction and optimization of therapeutic agents. These models correlate molecular descriptors with biological responses, enabling researchers to prioritize compounds with the greatest potential for success. The integration of medicinal chemistry with statistical and computational tools enhances rational drug design and accelerates discovery. By analyzing large datasets, researchers can identify key molecular features that drive potency and selectivity. Examples involving artemisinin derivatives, aminoquinolines, and other antimalarial scaffolds highlight how SAR and QSAR approaches inform drug design and address resistance mechanisms. This multidisciplinary approach—merging chemistry, biology, and data science—offers a powerful framework for developing more effective antimalarial agents. By leveraging SAR models and statistical insights, researchers can streamline drug development, reduce experimental burden, and create targeted therapies. The review emphasizes that a data-driven strategy is essential to combat the evolving threat of malaria and ensure the continued efficacy of antimalarial treatments.